However, noticeable weight loss usually takes several weeks because your body gradually adapts to the treatment
In the SURMOUNT-1 clinical trial, participants receiving tirzepatide 10 mg or 15 mg weekly achieved mean weight reductions of approximately 19.5% and 20.9% from baseline over 72 weeks, significantly exceeding placebo responses
Insurance does not cover it
Chhabra encourages patients to use this first week to practice mindful eating, as the diminished drive to eat allows you to focus on the quality of your nutrition rather than the quantity, setting the stage for long-term behavioral success
available for laboratory research use only Key data: 24.2% weight loss at 48 weeks (Phase 2), with Phase 3 including 4 mg maintenance dose alongside 9 mg and 12 mg For the full retatrutide approval status 2026 including the Eli Lilly Phase 3 timeline, EMA approval status, retatrutide availability across countries (including USA and Europe outside clinical trials), compounded retatrutide availability, retatrutide pricing, and where research-grade vendors like Core Peptides and Paradigm Peptides fit see our dedicated regulatory breakdown
